Amy Bachrodt's most recent trade in Maze Therapeutics Inc. was a trade of 32,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 16,000 | 16,000 | - | - | Restricted Stock Units | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Mar 2026 | 5,000 | 17,965 | - | 10.4 | 52,100 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 5,000 | 36,333 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 45.47 per share. | 02 Mar 2026 | 3,700 | 12,965 | - | 45.5 | 168,237 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 44.44 per share. | 02 Mar 2026 | 1,300 | 16,665 | - | 44.4 | 57,774 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 4,844 | 3,025 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Feb 2026 | 4,844 | 17,809 | - | 10.4 | 50,474 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 46.03 per share. | 02 Feb 2026 | 4,064 | 13,701 | - | 46.0 | 187,068 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 46.63 per share. | 02 Feb 2026 | 736 | 12,965 | - | 46.6 | 34,321 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 44.15 per share. | 02 Feb 2026 | 200 | 17,765 | - | 44.2 | 8,830 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 156 | 41,333 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Feb 2026 | 156 | 17,965 | - | 10.4 | 1,626 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 45.52 per share. | 22 Jan 2026 | 5,000 | 12,965 | - | 45.5 | 227,612 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 2,503 | 7,869 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 22 Jan 2026 | 2,503 | 17,965 | - | 10.4 | 26,081 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 22 Jan 2026 | 2,497 | 15,462 | - | 10.4 | 26,019 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 2,497 | 486 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Jan 2026 | 4,796 | 17,965 | - | 10.4 | 49,974 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 4,796 | 2,983 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 02 Jan 2026 | 2,595 | 12,965 | - | 39.6 | 102,681 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 38.70 per share. | 02 Jan 2026 | 2,405 | 15,560 | - | 38.7 | 93,072 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Jan 2026 | 204 | 13,169 | - | 10.4 | 2,126 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 204 | 2,377 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 9,876 | 23,834 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 29 Dec 2025 | 9,876 | 22,965 | - | 10.4 | 102,908 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 40.54 per share. | 29 Dec 2025 | 9,400 | 13,565 | - | 40.5 | 381,071 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 29 Dec 2025 | 5,000 | 12,965 | - | 40.1 | 200,407 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 2,605 | 2,581 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 29 Dec 2025 | 2,605 | 17,965 | - | 10.4 | 27,144 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 29 Dec 2025 | 2,395 | 15,360 | - | 10.4 | 24,956 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 2,395 | 1 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Sale of securities on an exchange or to another person at price $ 41.16 per share. | 29 Dec 2025 | 600 | 12,965 | - | 41.2 | 24,695 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 29 Dec 2025 | 124 | 13,089 | - | 10.4 | 1,292 | Common Stock |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 124 | 2,396 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Amy Bachrodt | SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2025 | 22,000 | 22,000 | - | - | Restricted Stock Units |